Amyloidoses are a group of diseases where abnormal fibrillar protein deposits accumulate in patients' tissues. In familial amyloidosis of the Finnish type (FAF), or gelsolin-related amyloidosis, the amyloid subunit protein consists of gelsolin peptides of amino acids 173-243 with the disease causing substitution at Asp187. Gelsolin is an actin-modulating protein and exists in both secretory and intracellular forms both encoded by a single gene in chromosome 9. We have previously shown that the FAF-associated forms of secretory gelsolin carrying the Asp187Asn or Asp187Tyr mutations are abnormally processed in cells, resulting in the secretion of an aberrant 68 kDa carboxyterminal fragment. Here we demonstrate by N-terminal sequencing that the amino terminus of this abnormal fragment is the amino acid 173 and thus represents the N-terminus of the FAF amyloid. We also provide evidence that the same truncated gelsolin can be found among the aberrant gelsolin fragments detected in patients' CSF. Finally, we also expressed the FAF-associated forms of intracellular gelsolin in COS-1 cells, and found no abnormality in their processing opposite to secretory form. Our results provide strong evidence that the secretory gelsolin is solely responsible for the amyloid formation in FAF.
INTRODUCTION
Amyloidosis comprises a group of diseases where abnormal fibrillar protein deposits are found in the tissues of patients. These deposits have a β-pleated structure showing typical green birefringence under Congo-red staining (1) . Familial amyloidosis of the Finnish type (FAF), or gelsolin-related amyloidosis (AGel), is a familial amyloid polyneuropathy and is characterized by corneal lattice dystrophy and progressive cranial, especially facial, and peripheral neuropathy (2) . There are 400-600 FAF patients in Finland (3), whereas only a few cases have been reported in other countries. The amyloid fibrils accumulating in the tissues of FAF patients are peptides consisting of amino acid residues 173-243 of gelsolin (4, 5) . Gelsolin is an actin-binding protein which exists both in intracellular and secretory (plasma) forms (6) . A single gene in chromosome 9 encodes both these forms of gelsolin (7, 8) but the transcription initiation sites and message splicing of the two forms are different (9) . At the protein level they differ only by the presence of a 25 N-terminal amino acid extension (plasma extension) in secretory gelsolin (6) . Both forms of gelsolin can sever actin filaments, nucleate actin filament assembly and block the fast-growing ends of actin under the control of calcium and polyphosphoinositides (10, 11) . Knock-out mice carrying a disrupted gelsolin gene have defects in platelet activation during hemostasis, inflammatory response, leukocyte motility and dermal fibroblast function in vivo (12) .
FAF is caused by an amino acid substitution where Asp187 has changed either to Asn or to Tyr (13) (14) (15) . This replacement is due to a point mutation where the G654 nucleotide of gelsolin cDNA has changed either to A or to T (15) (16) (17) . FAF patients represent several aberrant, presumably carboxyterminal gelsolin fragments of size 60-70 kDa in their cerebrospinal fluid (CSF) and serum (18) (19) (20) . We have earlier shown that both disease-associated forms of secretory gelsolin (Asn187 and Tyr187) are abnormally processed in COS-1 cells, resulting in the secretion of a 68 kDa carboxyterminal gelsolin fragment into the culture medium. We have suggested that this aberrant cleavage would be the initial event which triggers the cascade of pathological events leading to FAF, and the 68 kDa secreted gelsolin fragment in all likelihood represents the precursor for FAF amyloid (21) . However, the precise character of the abnormal cleavage as well as the interference of the FAF mutation in the processing of the intracellular form of gelsolin has so far remained unknown.
Here we ascertained the precise abnormal proteolytic cleavage site of the mutant secretory gelsolin. We also provide evidence that the aberrant fragments found in patients' CSF truly represent the carboxyterminal part of gelsolin and that the aberrant 68 kDa fragment secreted from the mutant COS cells is among them. We also monitored the cellular processing of the intracellular FAF gelsolin in the COS cell expression system, and our data suggest that mutant secretory gelsolin is the sole contributor to the formation of FAF amyloid.
*To whom correspondence should be addressed COS-1 cells were transfected with cDNA coding for wild type (Asp187) and mutant (Asn187) secretory gelsolin, blotted and stained with NH951 and anti-gelsolin antibody (see Fig. 2 for description of the antibodies). As a reference, after restaining with anti-gelsolin antibody, the 68 kDa extra fragment is shown. s, secretory; -, background of COS-1 cells
RESULTS
Demonstration of the amino terminus of the 68 kDa aberrant fragment of mutant (Asn187) secretory gelsolin COS-1 cells were transfected with the pCD-X expression construct coding for mutant (Asn187) secretory gelsolin as described earlier (21) . Immunoblotting of the culture medium revealed both the 83 kDa full-size gelsolin and the aberrant 68 kDa fragment to be in accordance with our previous data (21) . These fragments were partially purified and after SDS-PAGE and blotting were placed on a PVDF membrane for N-terminal sequencing. The 83 kDa band gave the sequence Ala-Thr-AlaSer-Arg-Gly-Ala-Ser-Gln-Ala, corresponding to the N-terminus of the wild type gelsolin. When the 68 kDa band was analyzed for 12 Edman degradation cycles, two amino acid residues could be detected in each cycle, indicating that the band consisted of a mixture of two proteins. One of the sequences from this combination, Ala-Thr-Glu-Val-Pro-Val-Ser-Trp-Glu-Ser-Phe Asn, revealed a 100% match to the gelsolin sequence starting from position 173 of the secretory gelsolin (Fig. 1a) . The calculated molecular weight for this fragment is 63876 Da, which is slightly less than the molecular weight assumed from its mobility on SDS-PAGE. The remaining part of the determined double sequence, Ile-Pro-Leu-Asp-Pro-Val-Ala-Gly-Tyr-Lys-Glu-Pro, corresponded to the N-terminal sequence of the α2-HS glycoprotein precursor (Fetuin) (GCG, SWISS PROT), a constituent of the cell growth medium.
Western analysis of wild type and mutant secretory gelsolin and patients' CSF with NH951 antibody
The abnormal cleavage site determined by N-terminal sequencing was further confirmed by western blot analysis using the NH951 antibody, which recognizes the amino terminal part of gelsolin (amino acids 1-172). The expression constructs coding for wild type (Asp187) and mutant (Asn187) secretory gelsolin were used for transfection of COS-1 cells and the media was analyzed by immunoblotting. As expected, the NH951 antibody did not recognize the aberrant 68 kDa fragment of the mutant secretory gelsolin in western blot analysis (Figs 1b, 2) .
This antibody was also used for immunoblot analysis of patients' CSF which we have earlier shown to expose two aberrant gelsolin fragments of 60-70 kDa (18) . To confirm whether these fragments truly represent the carboxyterminal part of gelsolin, 10 µg of CSF was used in western analysis. In accordance with our previous data, anti-gelsolin antibody detected two aberrant fragments of 60-70 kDa in patients' CSF, while AM904 antibody detected only the higher molecular weight aberrant fragment of about 70 kDa ( Fig. 2 and Fig. 3 ). Since the NH951 antibody did not recognize these fragments (Fig. 3) , the 70 kDa gelsolin polypeptide found in patients' CSF is likely to represent the same fragment of gelsolin which we observed by expressing the mutant secretory gelsolin in the COS-1 cells (21).
Processing of mutant secretory gelsolin
In order to monitor the cellular processing of the mutant secretory gelsolin, the transfected COS-1 cells were metabolically labeled with a mixture of 35 S cysteine and 35 S methionine for 2 h, chased for 0, 1, 4 and 16 h and the media were analyzed by immunoprecipitation with anti-gelsolin antibody followed by SDS-PAGE and fluorography. After 2 h pulse both the polypeptide band corresponding to the 83 kDa secretory gelsolin and the 68 kDa aberrant fragment were detected in the medium, indicating that mutant secretory gelsolin is secreted from the cells on a time scale close to that observed for the wild type (Fig. 4) . After 1, 4 and 16 h chase the 68 kDa fragment could still be detected in the immunoprecipitate (data not shown). These results suggest that intracellular processing of the mutant secretory gelsolin closely resembles that of the wild type protein, the only aberration being the sensitivity of the mutant gelsolin to single proteolytic cleavage, which results in the secretion of the abnormal 68 kDa fragment.
Expression of the wild type and mutant forms of intracellular gelsolin in COS-1 cells
To monitor the effect of FAF mutation on the metabolism of the intracellular form of gelsolin, constructs coding for the wild type (Asp187) and mutant (Asn187 and Tyr187) forms of intracellular gelsolin ( Fig. 5) were expressed in COS-1 cells and both the media and cells were analyzed by immunoblotting using antibodies which recognize different epitopes of gelsolin (Fig. 2) .
The polypeptide patterns in cultures expressing the wild type and mutant forms of intracellular gelsolin were identical on western blots (Fig. 6a) . The 80 kDa major band corresponding to For COS-cell expression, the wild type (Asp187) and mutant (Asn187 and Tyr187) gelsolin cDNAs coding for secretory gelsolin were digested with NarI to disrupt the transcription initiation site for secretory gelsolin (Met-27 ) and inserted into the pCD-X vector.
full-length intracellular gelsolin was equally detectable in all samples using all antibodies. In addition, smaller gelsolin fragments of around 35-55 kDa could also be detected, especially when the K572 and AM904 antibodies were used (Fig. 6b ), but none of these fragments were specific either to the wild type or mutant forms of intracellular gelsolin and none of them co-migrated either with the 68 kDa aberrant fragment found in the medium of the cells expressing mutant secretory gelsolin or with the 8-12 kDa FAF amyloid protein (Fig. 6) . A small leakage of intracellular gelsolin into the medium was occasionally observed (Fig. 6a) , which could have been due to the disruption of a minor portion of the cells. A slight background expression of gelsolin in COS-1 cells was also observed.
To analyze whether the mutant forms of intracellular gelsolin are more prone to fragmentation than the wild type, the transfected cells were incubated without proteinase inhibitors at +4_C, room temperature and +37_C for periods of 2 h-overnight. However, immunoblotting analyses revealed no difference between the polypeptide patterns of the wild type and mutated gelsolin after these experiments. In particular, there was no polypeptide of the size of the aberrant secretory fragment (68 kDa) (21) or of FAF amyloid (8-12 kDa) (4, 5) detectable in the cell cultures expressing the mutant intracellular gelsolin (data not shown).
Cellular processing and localization of the wild type and mutant forms of intracellular gelsolin
The processing of the intracellular wild type (Asp187) and mutant forms (Asn187 and Tyr187) of gelsolin were studied by pulse-chase experiments. The transfected COS-1 cells were metabolically labeled with 35 S cysteine and 35 S methionine for 2 h, chased for 0, 1, 4 and 16 h and analyzed by SDS-PAGE after immunoprecipitation with monoclonal anti-gelsolin antibody. After 2 h pulse time and the various chase times, no difference between the wild type and mutant forms of intracellular gelsolin could be detected. Both the wild type and mutant forms of intracellular gelsolin migrated with an apparent molecular weight of 80 kDa on western blots (Fig. 7) .
The cellular distribution of the expressed intracellular gelsolin was visualized by immunofluorescence staining with anti-gelsolin antibody. This analysis showed that both the wild type and mutant forms of gelsolin were homogeneously distributed throughout the cytoplasm. They were also partially associated with the fibrillar network of COS-1 cells (Fig. 8) . The data indicate that the Asn187 and Tyr187 mutant intracellular gelsolin polypeptides are expressed in similar quantities, and exhibit an intracellular distribution and stability closely similar to that of wild type gelsolin.
DISCUSSION
Amyloidogenesis characteristically involves some specific amyloidogenic protein precursors, which are converted into amyloid fibrils by different potential mechanisms. Proteolysis, in particular, is likely to play a central role in various types of amyloidosis, as concluded by the observation that many amyloid peptides are fragments of larger precursor proteins. Our in vitro expression studies have earlier demonstrated that the FAF associated forms of secretory gelsolin (with Asn187 or Tyr187 mutation) are subjected to abnormal proteolysis in cells, resulting in the secretion of an aberrant 68 kDa carboxyterminal fragment (21). Here we determined the amino terminal sequence of this fragment with Asn187 mutation to be at amino acid position 173 of gelsolin. This provides strong evidence that the abnormal fragment truly represents the precursor protein for FAF amyloid, known to consist of amino-acids 173-244 of gelsolin (4, 5) The possibility that mutant secretory gelsolin would be retained for exceptionally long times in the secretory pathway and become fragmented was ruled out by the pulse-chase experiments which Figure 9 . Hypothesis of the pathological events leading to FAF. The transcription initiation site and splicing of the intracellular and secretory gelsolin transcripts are different (9) . Patients have an amino acid substitution of Asp187 to Asn187 (13, 14) or to Tyr187 (15) , which occurs in both intracellular and secretory forms of gelsolin. For intracellular mutant gelsolin there is no evidence of abnormal processing or transport, whereas mutant secretory gelsolin is cleaved aberrantly in the terminal phase of the secretory pathway, probably on the plasma membrane, resulting in the secretion of the aberrant 68 kDa carboxyterminal fragment (21) . This fragment carries the first amino acid (173) of the FAF amyloid protein on its aminoterminus, and the same polypeptide can presumably also be found in the CSF of the patients. A second putative cleavage at the carboxyterminus of the FAF amyloid protein at amino acid position 244 or 247 (20) generates the FAF amyloid protein (8-12 kDa) (4,5) which accumulates in the tissues of patients.
showed that the aberrant gelsolin fragment is secreted within the same time scale as the normal full-length gelsolin. Since the proteolysis of mutant secretory gelsolin occurs in cells (21) , this 'first hit' seems to be a triggering prefibrillogenic event and thus crucial for the pathogenesis of FAF. Our demonstration of the novel proteolytic cleavage site at FAF gelsolin between amino acids 172-173 is in accordance with structural analyses of wild type gelsolin segment 1-actin complex, which have suggested that the FAF mutation at position 187 could cause local rearrangements in the gelsolin structure, leaving amino acid 172 (Arg) more accessible to proteases (22) . Further, our data from western analysis strongly suggest that the mutant 68 kDa gelsolin fragment secreted from the cells can also be found among the abnormal carboxyterminal fragments in the CSF of the patients (18) , where this polypeptide could represent the precursor for FAF amyloid, found extensively in the meninges of the patients (Fig. 9, right) (23) . To our knowledge, a similar pathological proteolytic processing of a larger precursor protein for amyloid has so far been demonstrated in cell cultures only in the case of Alzheimer's disease where the Swedish double mutation in APP altered the cleavage of the mutant APP within the secretory pathway (24) .
It has been discussed whether amyloidosis is an intracellular or extracellular phenomenon. Intracellular amyloid deposits have, for example, been found in pancreatic β-cells of patients with adult onset diabetes (25) and in cells expressing islet amyloid polypeptide (26) , but most amyloid deposits are found extracellularly, such as gelsolin deposits in FAF (23) . However, fibrillogenesis could initially be an intracellular event, and the peptides would only subsequently be released into the extracellular space after cell death. Interestingly, the FAF mutation in nucleotide 654 of the gelsolin gene is located in an area of the coding region that is shared both by intracellular and secretory gelsolin. Until now it has remained unknown whether both these forms of gelsolin contribute to the molecular pathogenesis of FAF.
Here we found no difference between the expression of the wild type and mutant forms of intracellular gelsolin. They were expressed in similar quantities, displayed equal stability and their polypeptide patterns in electrophoresis were the same. These results would suggest that the intracellular form of mutant gelsolin does not contribute to the amyloid formation in FAF (Fig.  9, left) . However, stable gelsolin-expressing cell lines would be highly useful in analyzing the long-term effects of mutant intracellular gelsolin.
Immunofluorescence analyses demonstrated that intracellular gelsolin is homogeneously distributed throughout the cytoplasm and partially associates with the network system (actin) of COS cells, as has also been demonstrated in fibroblasts (27) . This indicates that in vivo gelsolin is distributed into a cytoskeletalbound fraction and a soluble cytoplasmic fraction (27) . Since the cellular distribution of wild type and mutant intracellular gelsolin were similar, it seems that the FAF mutation in intracellular gelsolin does not influence its actin-binding capacity. Gelsolinlacking mice display defects in hemostasis and platelet activation, inflammatory response and leucocyte motility and dermal fibroblast function in vivo (12) , while FAF patients show symptoms and signs of progressive cranial neuropathy, corneal lattice dystrophy and distal sensorimotor neuropathy (2, 28) . These data would indicate that FAF patients' symptoms are caused by the accumulation of amyloid in the tissues, not by the disturbed function of mutant gelsolin. It is interesting that the actin filament severing capacity of the plasma of a homozygous patient is reduced (29) , but this might simply be due to the fragmentation of mutant plasma gelsolin in the analyzed samples. However, to ascertain the true functional impact of the FAF mutations on gelsolin, in vitro assays designed to reveal functional disturbances in mutant gelsolin are needed.
In conclusion, our data provide evidence that intracellular mutant gelsolin is not involved in the amyloidogenic events occurring in FAF. The mutated secretory form of gelsolin seems to be subjected to abnormal proteolysis resulting in the generation of a carboxyterminal polypeptide, also detectable in patients' CSF. This fragment carries the FAF amyloid sequence precisely on its aminoterminus and thus in all likelihood represents the precursor for FAF amyloid.
MATERIALS AND METHODS

Construction of expression plasmids
The wild type (Asp187) and mutant (Asn187 and Tyr187) gelsolin cDNAs coding for secretory gelsolin (21) were digested with NarI (Pharmacia Biotech, USA) which cleaves gelsolin cDNA at nucleotide 129 and disrupts the initiation site of the secretory gelsolin. The intracellular gelsolin cDNA was then removed from the pCD-X vector (30) by EcoRI (Pharmacia Biotech, USA) digestion, blunt-ended and subcloned into the SmaI (New England BioLabs, USA) site of the pCD-X vector (Fig. 5) . Clones with the insert in the correct orientation were identified by restriction enzyme mapping. The correct nucleotide sequence of the clones was confirmed by dideoxynucleotide sequencing (31).
Antibodies
Antibodies which recognize different epitopes of gelsolin were used in the assays (Fig. 2) . K572 and AM904 antibodies are described in detail elsewhere (21) . Monoclonal anti-gelsolin (Sigma Chemicals, St. Louis, USA) is specific for a 47 kDa peptide derived from a chymotryptic cleavage extending to the carboxyterminus of the protein (32) . K572 rabbit antiserum was raised against a synthetic peptide of amino acid residues 231-242 located on the carboxyterminus of the amyloid part of gelsolin (21) . AM904 rabbit antiserum was raised against gelsolin fragments extracted from amyloid in the tissues of a patient (21) . To obtain the gelsolin polypeptides containing the amino terminal (amino acids 1-172, corresponding to the NH951 antibody) and amyloid-forming (amino acids 173-244, corresponding to the AM951 antibody) sequences of gelsolin, the gelsolin cDNAs coding for each part of the protein were amplified by PCR and cloned into the BamH1 site of the pGEX-2T fusion vector (Pharmacia Biotech, USA). The correct nucleotide sequence of each clone was confirmed by dideoxynucleotide sequencing (31) . The polypeptides were expressed as a glutathione S-transferase (GST) fusion protein in E.coli strain BL21 and purified on 8 and 10% preparative SDS-PAGE. Rabbits were immunized by subcutaneous injection with 200-250 µg of the fusion protein in Freund's complete adjuvant, which was repeated twice after 2 and 6 weeks. Blood was collected 1 week after the last immunization and the antibody titers and specificity were determined by western blotting (33) .
Transfection and harvesting of COS-1 cells
Transfections were carried out as described earlier (21) . Briefly, COS-1 cells (ATCC CLR 1650) (American Type Culture Collection) cultured in Dulbecco's modified Eagle's medium (DMEM) with antibiotics, glutamine and 10% fetal calf serum (FCS) were seeded at a confluence of 2-4 × 10 5 cells/3 cm dish 1 day prior to transfection. The cells were transfected either with 10 µg of the pCD-X constructs using the DEAE dextran method (34) or with 3 µg of the pCD-X constructs using the liposome transfection method (35) . Serum-free medium was added 48 h after transfection, and after an overnight incubation, the medium was collected and the cells harvested by trypsinization. Protease inhibitors (EDTA, 1.2 mg/ml, Merck, Germany; PMSF, 1 mM, Sigma Chemicals, St. Louis, USA; E-64c, 0.1 mM, Boehringer Mannheim, Germany; Aprotinin 2 µg/ml, Boehringer Mannheim, Germany) were used in collection and further experiments, unless stated otherwise. After harvesting, the cells were homogenized in DMEM, washed with ice-cold PBS and lysed by freeze-thawing in the phosphate buffer with 1% Triton X-100.
Immunoblotting
The protein concentrations of the samples were analyzed by Bio-Rad's protein detection assay (36) . 10 µg of cell samples in 1 × Laemmli buffer and 3 % β-mercaptoethanol were run on 9 to 14% SDS polyacrylamide gel and electroblotted. The proteins were detected both by color detection using AP-conjugated secondary anti-mouse or anti-rabbit antibodies (DAKO, Denmark) or with enhanced chemiluminescence (ECL, Amersham, UK) using peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies (DAKO, Denmark) as described earlier (21) . For restaining, the primary and secondary antibodies were removed from the ECL filters by incubating in 62.5 mM Tris-HCl pH 6.7, 2% SDS, 100 mM β-mercaptoethanol for 30 min at 50_C.
N-terminal sequencing
The COS-1 cells were transfected with the secretory form of mutant (Asn187) gelsolin as described earlier (21) and the cell growth medium (about 40 ml) was concentrated to 0.8 ml using a Novacell NC 10 Omega membrane concentrator (Filtron Technology Corporation, MA, USA). The concentrate was then subjected in 400 µl portions to gel filtration in a Superdex HR 10/30 column (Pharmacia Biotech, Sweden) in 50 mM sodium phosphate pH 7.4, 150 mM NaCl at a flow rate of 0.5 ml/min. The collected fractions (0.5 ml) were analyzed by SDS-PAGE followed by immunoblotting. Gelsolin-containing fractions were further purified by reversed phase chromatography on a 0.21 × 4 cm TSK 250 TMS (C1, 5 µm, 250 Å) column (Tosoh Corporation, Japan) using a linear gradient of acetonitrile (3-100% in 60 min) in 0.1% trifluoroacetic acid at a flow rate of 200 µl/min. The collected fractions were analyzed by immunoblotting as above. The fractions containing the 83 kDa secretory gelsolin and the 68 kDa fragment of interest were dried in a vacuum centrifuge. Corresponding gelsolin fractions from six repeated reversed phase chromatography runs were combined and subjected to SDS-PAGE on 10% gel followed by blotting on a PVDF membrane (37) . The protein bands on the membrane were visualized by staining with Coomassie Brilliant Blue. The 83 kDa bands and 68 kDa bands, also localized by parallel immunoblotting, were individually cut out and subjected to N-terminal sequence analysis on an Applied Biosystems Procise 494 A sequencer. The results were analyzed using an Applied Biosystems 610A Data Analysis System (Perkin Elmer Corporation, USA).
Pulse-labeling and immunoprecipitation
Transfected cells were starved in cysteine-and methionine-free medium for 30 min and thereafter labeled with a mixture of 100 µCi/ml of 35 S cysteine and 100 µCi/ml of 35 S methionine (Amersham, UK) for 2 h in cysteine-and methionine-free medium. The media and the cells were collected either after 2 h pulse time or subjected to 0 h, 1 h, 4 h and 16 h chase in DMEM without FCS. The cells and media were collected and the media concentrated by Centricon 3-30 (Amicon, Beverly, MA,USA). Immunoprecipitations were carried out with anti-gelsolin antibody at a 1:200 dilution as described earlier (21) , with the following modifications: 0.1% SDS and 0.5% natriumdesoxycholate were added to the immunoprecipitation buffer and washing buffer I.
Immunofluorescence analyses and immunoelectron microscopy
The cells were seeded on 12 mm coverslips and grown to 30-50% confluency overnight after transfections using the lipofectin method (35) . The cells were fixed in freshly made 4% paraformaldehyde for 30 min at room temperature and after washing twice with PBS, permeabilized by incubating for 15 min in blocking buffer (PBS containing 0.5% BSA and 0.2% saponin). This was followed by incubation of anti-gelsolin antibody at a 1:500 dilution in the blocking buffer for 45 min. The cells were rinsed three times with blocking buffer and stained with a 1:50 dilution of rhodamine-conjugated rabbit anti-mouse IgG (DAKO, Denmark) in blocking buffer for 45 min at room temperature. After staining, the cells were rinsed three times with PBS and the coverslips were mounted in glycerol or in Mowiol and viewed with a Zeiss Axiophot immunofluorescence microscope using a 63× objective.
